Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma von Moreno, V., Sepulveda, J.M., Vieito, M., Hernández-Guerrero, T., Doger, B., Saavedra, O., Ferrero, O., Sarmiento, R., Arias, M., De Alvaro, J., Di Martino, J., Zuraek, M., Sanchez-Pérez, T., Aronchik, I., Filvaroff, E.H., Lamba, M., Hanna, B., Nikolova, Z., Braña, I.

Volltext

Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. Characterization of chimeric and truncate... von Feng, X.H. (University of California, San Francisco, CA.), Filvaroff, E.H, Derynck, R

Volltext

A slow release formulation of insulin as a treatment for osteoarthritis von Cai, L., Okumu, F.W., Cleland, J.L., Beresini, M., Hogue, D., Lin, Z., Filvaroff, E.H.

Volltext

Inhibition of myogenic differentiation in myoblasts expressing a truncated type II TGF-beta receptor von FILVAROFF, E. H, EBNER, R, DERYNCK, R

Volltext